Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Diabetologia
Published in: Diabetologia 1/2013

01-01-2013 | Article

Fasting plasma glucose and HbA1c in cardiovascular risk prediction: a sex-specific comparison in individuals without diabetes mellitus

Authors: B. Schöttker, H. Müller, D. Rothenbacher, H. Brenner

Published in: Diabetologia | Issue 1/2013

Login to get access

Abstract

Aims/hypothesis

This study aimed to assess the cardiovascular risk of individuals with fasting plasma glucose (FPG)- and/or HbA1c-defined prediabetes (5.6–6.9 mmol/l and 39–47 mmol/mol [5.7–6.4%], respectively) or manifest diabetes mellitus and to evaluate whether FPG or HbA1c can improve risk prediction beyond that estimated by the Systematic Coronary Risk Evaluation (SCORE) chart in individuals without diabetes mellitus.

Methods

Cox regression was employed to estimate HRs for primary incident cardiovascular events (CVEs) in a cohort of 8,365 individuals aged 50–74 years. Furthermore, HbA1c and FPG were added individually to the variables of the SCORE and measures of model discrimination and reclassification were assessed.

Results

During 8 years of follow-up, 702 individuals had a primary CVE. After adjusting for conventional cardiovascular risk factors, HRs were attenuated close to one for the prediabetes groups (especially for women), whereas a 1.7- and a 1.9-fold increased risk persisted for men and women with diabetes, respectively. Extension of the SCORE variables by either FPG or HbA1c did not improve its predictive abilities in individuals without diabetes. There was a non-significant net reclassification improvement for men when HbA1c was added (2.2%, p = 0.16).

Conclusions/interpretation

The increased cardiovascular risk of individuals with FPG- or HbA1c-defined prediabetes can mainly be explained by other cardiovascular risk factors. Adding FPG or HbA1c did not significantly improve CVE risk prediction by the SCORE variables in individuals without diabetes mellitus.
Appendix
Available only for authorised users
Literature
1.
Wannamethee SG, Shaper AG, Whincup PH, Lennon L, Sattar N (2011) Impact of diabetes on cardiovascular disease risk and all-cause mortality in older men: influence of age at onset, diabetes duration, and established and novel risk factors. Arch Intern Med 171:404–410PubMedCrossRef
2.
Sarwar N, Aspelund T, Eiriksdottir G et al (2010) Markers of dysglycaemia and risk of coronary heart disease in people without diabetes: Reykjavik prospective study and systematic review. PLoS Med 7:e1000278PubMedCrossRef
3.
Hanna-Moussa A, Gardner MJ, Kurukulasuriya LR, Sowers JR (2009) Dysglycemia/prediabetes and cardiovascular risk factors. Rev Cardiovasc Med 10:202–208PubMed
4.
Consensus Committee (2007) Consensus statement on the worldwide standardization of the hemoglobin A1C measurement. The American Diabetes Association, European Association for the Study of Diabetes, International Federation of Clinical Chemistry and Laboratory Medicine, and the International Diabetes Federation. Diabetes Care 30:2399–2400CrossRef
5.
American Diabetes Association (2012) Diagnosis and classification of diabetes mellitus. Diabetes Care 35(Suppl 1):S64–S71CrossRef
6.
Ford ES, Zhao G, Li C (2010) Pre-diabetes and the risk for cardiovascular disease: a systematic review of the evidence. J Am Coll Cardiol 55:1310–1317PubMedCrossRef
7.
Selvin E, Steffes MW, Zhu H et al (2010) Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. N Engl J Med 362:800–811PubMedCrossRef
8.
Cederberg H, Saukkonen T, Laakso M et al (2010) Postchallenge glucose, A1C, and fasting glucose as predictors of type 2 diabetes and cardiovascular disease: a 10-year prospective cohort study. Diabetes Care 33:2077–2083PubMedCrossRef
9.
Simmons RK, Sharp S, Boekholdt SM et al (2008) Evaluation of the Framingham risk score in the European Prospective Investigation of Cancer-Norfolk cohort: does adding glycated hemoglobin improve the prediction of coronary heart disease events? Arch Intern Med 168:1209–1216PubMedCrossRef
10.
Bersoux S, Cook CB, Wu Q et al (2011) Hemoglobin A1c testing alone does not sufficiently identify patients with prediabetes. Am J Clin Pathol 135:674–677PubMedCrossRef
11.
Lorenzo C, Wagenknecht LE, Hanley AJ, Rewers MJ, Karter AJ, Haffner SM (2010) A1C between 5.7 and 6.4% as a marker for identifying pre-diabetes, insulin sensitivity and secretion, and cardiovascular risk factors: the Insulin Resistance Atherosclerosis Study (IRAS). Diabetes Care 33:2104–2109PubMedCrossRef
12.
Schöttker B, Raum E, Rothenbacher D, Müller H, Brenner H (2011) Prognostic value of haemoglobin A1c and fasting plasma glucose for incident diabetes and implications for screening. Eur J Epidemiol 26:779–787PubMedCrossRef
13.
American Diabetes Association (2010) Standards of medical care in diabetes–2010. Diabetes Care 33(Suppl 1):S11–S61CrossRef
14.
John WG, Mosca A, Weykamp C, Goodall I (2007) HbA1c standardisation: history, science and politics. Clin Biochem Rev 28:163–168PubMed
15.
Conroy RM, Pyorala K, Fitzgerald AP et al (2003) Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 24:987–1003PubMedCrossRef
16.
Pencina MJ, D’Agostino RB Sr, D’Agostino RB Jr, Vasan RS (2008) Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 27:157–172PubMedCrossRef
17.
Cook NR (2007) Use and misuse of the receiver operating characteristic curve in risk prediction. Circulation 115:928–935PubMedCrossRef
18.
Cook NR (2010) Methods for evaluating novel biomarkers—a new paradigm. Int J Clin Pract 64:1723–1727PubMedCrossRef
19.
Brunner EJ, Shipley MJ, Marmot MG, Kivimaki M, Witte DR (2010) Do the Joint British Society (JBS2) guidelines on prevention of cardiovascular disease with respect to plasma glucose improve risk stratification in the general population? Prospective cohort study. Diabet Med 27:550–555PubMedCrossRef
20.
Sarwar N, Gao P, Seshasai SR et al (2010) Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 375:2215–2222PubMedCrossRef
21.
Löw M, Stegmaier C, Ziegler H, Rothenbacher D, Brenner H (2004) [Epidemiological investigations of the chances of preventing, recognizing early and optimally treating chronic diseases in an elderly population (ESTHER study)]. Dtsch Med Wochenschr 129:2643–2647 [article in German]PubMedCrossRef
22.
Raum E, Rothenbacher D, Löw M, Stegmaier C, Ziegler H, Brenner H (2007) Changes of cardiovascular risk factors and their implications in subsequent birth cohorts of older adults in Germany: a life course approach. Eur J Cardiovasc Prev Rehabil 14:809–814PubMedCrossRef
23.
Cooney MT, Dudina A, de Bacquer D et al (2009) How much does HDL cholesterol add to risk estimation? A report from the SCORE investigators. Eur J Cardiovasc Prev Rehabil 16:304–314PubMedCrossRef
24.
May S, Hosmer DW (2004) A cautionary note on the use of the Gronnesby and Borgan goodness-of-fit test for the Cox proportional hazards model. Lifetime Data Anal 10:283–291PubMedCrossRef
25.
Mann DM, Carson AP, Shimbo D, Fonseca V, Fox CS, Muntner P (2010) Impact of HbA1c screening criterion on the diagnosis of pre-diabetes among US adults. Diabetes Care 33:2190–2195PubMedCrossRef
26.
Balkau B, Soulimane S, Lange C, Gautier A, Tichet J, Vol S (2011) Are the same clinical risk factors relevant for incident diabetes defined by treatment, fasting plasma glucose, and HbA1c? Diabetes Care 34:957–959PubMedCrossRef
27.
Pajunen P, Koukkunen H, Ketonen M et al (2005) Myocardial infarction in diabetic and non-diabetic persons with and without prior myocardial infarction: the FINAMI study. Diabetologia 48:2519–2524PubMedCrossRef
28.
Hu G, Jousilahti P, Qiao Q, Katoh S, Tuomilehto J (2005) Sex differences in cardiovascular and total mortality among diabetic and non-diabetic individuals with or without history of myocardial infarction. Diabetologia 48:856–861PubMedCrossRef
29.
Natarajan S, Liao Y, Cao G, Lipsitz SR, McGee DL (2003) Sex differences in risk for coronary heart disease mortality associated with diabetes and established coronary heart disease. Arch Intern Med 163:1735–1740PubMedCrossRef
30.
Selvin E, Marinopoulos S, Berkenblit G et al (2004) Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med 141:421–431PubMed
31.
Hamer M, Chida Y, Stamatakis E (2009) Utility of C-reactive protein for cardiovascular risk stratification across three age groups in subjects without existing cardiovascular diseases. Am J Cardiol 104:538–542PubMedCrossRef
32.
Lauritzen T, Sandbaek A, Skriver K, Borch-Johnson K (2011) HbA1c and cardiovascular risk score identify people who may benefit from preventive interventions: a 7 year follow-up of a high-risk screening programme for diabetes in primary care (ADDITION), Denmark. Diabetologia 54:1318–1326PubMedCrossRef
33.
Li G, Zhang P, Wang J et al (2008) The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study. Lancet 371:1783–1789PubMedCrossRef
34.
Ebrahim S, Taylor F, Ward K, Beswick A, Burke M, Davey SG (2011) Multiple risk factor interventions for primary prevention of coronary heart disease. Cochrane Database Syst Rev, Issue 1, Art. no.: CD001561. doi:10.​1002/​14651858.​CD001561.​pub3
Metadata
Title
Fasting plasma glucose and HbA1c in cardiovascular risk prediction: a sex-specific comparison in individuals without diabetes mellitus
Authors
B. Schöttker
H. Müller
D. Rothenbacher
H. Brenner
Publication date
01-01-2013
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 1/2013
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-012-2707-x

Other articles of this Issue 1/2013

Diabetologia 1/2013 Go to the issue

Article

Effects of 12 weeks’ treatment with a proton pump inhibitor on insulin secretion, glucose metabolism and markers of cardiovascular risk in patients with type 2 diabetes: a randomised double-blind prospective placebo-controlled study

Letter

Endoglin (CD105) is not a specific selection marker for endothelial cells in human islets of Langerhans. Reply to Wheeler-Jones CPD, Clarkin CE, Farrar CE et al [letter]

Erratum

Erratum to: A high-fat-diet-induced cognitive deficit in rats that is not prevented by improving insulin sensitivity with metformin

Article

Expression of the enteroviral capsid protein VP1 in the islet cells of patients with type 1 diabetes is associated with induction of protein kinase R and downregulation of Mcl-1

Article

Impact of early detection and treatment of diabetes on the 6-year prevalence of cardiac autonomic neuropathy in people with screen-detected diabetes: ADDITION-Denmark, a cluster-randomised study

Article

Direct effect of GLP-1 infusion on endogenous glucose production in humans
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits